Nucana Stock Price, News & Analysis

NuCana (NASDAQ: NCNA), a clinical-stage biopharmaceutical company focused on cancer treatments, has priced a $7 million registered direct offering of 10,845,985 American Depository Shares (ADSs) or pre-funded warrants. Each ADS or warrant is priced at $0.6454 and comes with two additional warrants: a Series A warrant to purchase one ADS at $0.8068 per share and a Series B warrant at $1.61 per share.

The proceeds will fund the company's drug discovery and development programs, along with general corporate purposes including working capital, investments, and potential acquisitions. The offering, managed by Laidlaw & Company as sole placement agent, is expected to close around May 7, 2025.

NuCana (NASDAQ: NCNA) has reported its Q4 and full-year 2024 financial results, highlighting progress in its anti-cancer drug development programs. The company's lead program, NUC-7738, showed promising results in combination with pembrolizumab, achieving disease control in 75% of patients with PD-1 inhibitor-resistant melanoma.

Financial highlights include cash position of £6.7 million as of December 31, 2024, with runway extended into Q3 2025. The company reported a reduced net loss of £19.0 million for 2024, compared to £27.6 million in 2023. Loss per share improved to £0.26 for 2024 from £0.53 in 2023.

Key 2025 milestones include initiating an expansion study of NUC-7738 with pembrolizumab for melanoma patients and seeking FDA guidance on pivotal study design. The company will also continue development of NUC-3373, which has shown positive results in combination studies.

Aurion Biotech has appointed Donald Munoz as Chief Financial Officer, reporting to CEO Greg Kunst. Munoz brings over 30 years of healthcare experience, including nine years as CFO of NuCana plc (NASDAQ: NCNA), where he led a $114 million IPO and $80 million follow-on offering. Previously, he served as CFO at NOXXON Pharma and spent 20 years as a healthcare investment banker at firms including Cowen & Company, Leerink Partners, and Deutsche Bank.

At NuCana, Munoz managed financial operations, investor relations, SEC reporting, audit, tax, and financial planning. Throughout his career, he has completed over 100 financing and strategic advisory transactions. The appointment follows Aurion's announcement of positive six-month top-line data from its CLARA Phase 1/2 clinical trial for AURN001, their lead product candidate targeting corneal endothelial disease.

NuCana reported Q3 2024 financial results and clinical updates. The company presented promising Phase 2 data for NUC-7738 in combination with pembrolizumab, showing disease control in 9 of 12 PD-1 inhibitor-resistant melanoma patients. Phase 1b/2 data for NUC-3373 showed encouraging results in combination with pembrolizumab or docetaxel. Financial highlights include cash position of £11.4 million as of September 30, 2024, with runway expected into Q2 2025. The company reported a reduced net loss of £4.5 million compared to £6.7 million in Q3 2023.

NuCana announced initial data from its Phase 1b/2 study of NUC-3373 in combination therapies. In Module 1, combining NUC-3373 with pembrolizumab showed promising results in 12 advanced solid tumor patients, achieving a 22% objective response rate and 67% disease control rate. Notable cases included a bladder cancer patient achieving 100% target lesion reduction and a melanoma patient showing 81% reduction. In Module 2, NUC-3373 with docetaxel demonstrated extended stable disease in lung cancer patients, with one achieving stability for over 13 months. The combinations were generally well-tolerated, though Module 2 enrollment was paused due to docetaxel-related toxicity concerns.

NuCana plc (NASDAQ: NCNA) has announced the issuance of a new composition-of-matter patent for NUC-7738 by the United States Patent and Trademark Office (USPTO). This patent (US12,054,510) is a important addition to NUC-7738's intellectual property protection, which now includes over 80 issued patents worldwide.

NUC-7738, a novel anti-cancer agent, is currently in a Phase 2 clinical study combined with pembrolizumab for PD-1 inhibitor resistant melanoma patients. Recent data presented at the ESMO Congress 2024 showed encouraging results, with the majority of patients achieving a progression-free survival of more than 5 months, compared to the current standard of care of 2-3 months.

Hugh S. Griffith, NuCana's CEO, emphasized the importance of this patent in strengthening NUC-7738's intellectual property protection and highlighted its potential to make previously resistant tumors sensitive to PD-1 inhibitor rechallenge.

NuCana plc (NASDAQ: NCNA) presented final data from the Phase 2 NuTide:701 study at the ESMO Congress 2024, showcasing encouraging results for NUC-7738 in combination with pembrolizumab for metastatic melanoma patients refractory to or relapsed on prior PD-1 inhibitor therapy. The study, involving 12 patients, demonstrated a 75% disease control rate, including two partial responses. Notably, 7 out of 12 patients achieved progression-free survival exceeding five months, which is significant for this patient population. The combination therapy also exhibited a favorable safety profile. NUC-7738's mechanism of action, targeting multiple aspects of the tumor microenvironment, is believed to sensitize PD-1 resistant tumors to rechallenge with PD-1 inhibitors.

NuCana plc (NASDAQ: NCNA) announced the discontinuation of its NuTide:323 study following a pre-planned analysis and recommendation from the Steering Committee. The study, which aimed to develop NUC-3373 as a replacement for 5-FU in second-line colorectal cancer treatment, was unlikely to achieve its primary objective of superior Progression Free Survival compared to the control arm.

Despite this setback, NuCana remains committed to its ongoing development programs. The company will continue with the NuTide:701 and NuTide:303 studies, focusing on NUC-7738 in combination with pembrolizumab. Encouraging data from these studies will be presented at the ESMO Annual Conference in September 2024.

NuCana plc (NASDAQ: NCNA) reported Q2 2024 financial results and provided a business update. Key points include:

- Cash and cash equivalents of £11.6 million as of June 30, 2024
- Net loss of £7.0 million for Q2 2024
- Loss per ordinary share of £0.12

The company is advancing clinical programs for NUC-3373 (ProTide transformation of 5-FU) and NUC-7738 (ProTide transformation of 3'-deoxyadenosine). Multiple data readouts are expected in H2 2024, including updates from Phase 2 studies in colorectal cancer and melanoma. NuCana anticipates its cash runway to extend into Q1 2025.